| Literature DB >> 34697550 |
Feng Zhao1, Yingjun Deng1, Guanchao Du1, Shengjing Liu1, Jun Guo1, Hao Wang1, Yazhou Chen1, Fu Wang1, Qiang Geng2.
Abstract
BACKGROUND: The traditional Chinese medicines Astragalus and Angelica are often combined to treat male infertility, but the specific therapeutic mechanism is not clear. Therefore, this study applies a network pharmacology approach to investigate the possible mechanism of action of the drug pair Astragalus-Angelica (PAA) in the treatment of male infertility.Entities:
Year: 2021 PMID: 34697550 PMCID: PMC8541871 DOI: 10.1155/2021/8281506
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Figure 1Technical strategy flow diagram.
Figure 2Targets of the PAA in male infertility treatment. The number in the blue circle is the unique target number of AS&AN, the number in the yellow circle is the unique target number of male infertility, and the middle number is the common target number common for both.
Figure 3The PPI networks of AS&AN for male infertility. (a) PPI network diagram of the core. (b) Frequencies of the top 20 core targets (the y-axis represents targets, and the x-axis represents the frequency).
Detailed data of the top 20 targets.
| Target | Degree | Betweenness centrality | Closeness centrality | MCODE score |
|---|---|---|---|---|
| MAPK1 | 44 | 0.11909067 | 0.40682415 | 3.181818182 |
| TP53 | 44 | 0.07271146 | 0.37349398 | 3.454545455 |
| AKT1 | 40 | 0.10656178 | 0.4005168 | 4.169117647 |
| Jun | 39 | 0.04830527 | 0.38993711 | 2.759259259 |
| AGT | 37 | 0.07377641 | 0.3583815 | 17 |
| RXRA | 35 | 0.10861121 | 0.40207523 | 6.222222222 |
| RELA | 31 | 0.0222772 | 0.3708134 | 2.675324675 |
| HSP90AA1 | 31 | 0.02770788 | 0.36470588 | 3.264705882 |
| NCOA1 | 30 | 0.03957597 | 0.37575758 | 6.222222222 |
| ANXA1 | 30 | 0.01792683 | 0.32460733 | 17 |
| EDN1 | 30 | 0.03558045 | 0.37530266 | 11 |
| EGFR | 29 | 0.04140608 | 0.36172695 | 8 |
| TNF | 29 | 0.03633951 | 0.36299766 | 2.810526316 |
| NR3C1 | 28 | 0.0253214 | 0.38130381 | 2.685714286 |
| MED1 | 27 | 0.03261089 | 0.36172695 | 6.222222222 |
| ADCY1 | 27 | 0.01606181 | 0.31155779 | 17 |
| ESR1 | 26 | 0.04038295 | 0.37621359 | 2.947368421 |
| IL6 | 26 | 0.02207884 | 0.35107588 | 6 |
| PPARA | 25 | 0.05492241 | 0.39340102 | 6.222222222 |
| VEGFA | 25 | 0.02270293 | 0.35227273 | 2.911764706 |
Figure 4The drug pair-component-target-disease regulation network. The red node is the traditional Chinese medicine, the yellow node is the active ingredient, the green node is the target, the orange node between the two circles is the common active ingredient of Astragalus and Angelica, and the dark green node is the common target of Astragalus and Angelica.
Figure 5Top 10 of GO enrichment: (a) top 10 of GO enrichment (BP), (b) results of GO enrichment (MF), and (c) results of GO enrichment (CC) (the y-axis represents top 10 BP/MF/CC terms, and the x-axis represents the enrichment factors.).
Male-infertility-related pathways and involved targets.
| Description | Count | Targets |
|---|---|---|
| cAMP signaling pathway | 18 | ACOX1, ADCY1, ADRB2, AKT1, CFTR, CHRM2, CREB1, DRD2, EDN1, EDNRA, FOS, HTR1A, NFKB1, NFKBIA, PPARA, PRKCA, MAPK1, SST |
| PI3K-Akt signaling pathway | 20 | AKT1, CCND1, CDK2, CDKN1A, CHRM2, CREB1, EGF, EGFR, HSP90AA1, HSP90AB1, IL4, IL6, KDR, NFKB1, NOS3, PRKCA, MAPK1, RXRA, TP53, FGF23 |
| IL-17 signaling pathway | 12 | CASP8, FOS, HSP90AA1, HSP90AB1, IFNG, IL1B, IL4, IL6, IL13, NFKB1, NFKBIA, MAPK1 |
| FOXO signaling pathway | 11 | AKT1, CCND1, CAT, CDK2, CDKN1A, EGF, EGFR, IL6, MAPK1, SLC2A4, TGFB1 |
| MAPK signaling pathway | 13 | AKT1, EGF, EGFR, FOS, IL1B, IL6, KDR, NFKB1, PRKCA, MAPK1, TGFB1, TP53, FGF23 |
Figure 6Top 20 of KEGG enrichment (the y-axis represents top 20 of KEGG terms, and the x-axis represents the rich factors).
Docking results.
| Ligand | Receptor (PDB ID) | Lowest binding energy (kJ/mol) |
|---|---|---|
| Stigmasterol | EGF (1nql) | −14.0 |
| Stigmasterol | EGFR (5ug9) | −11.5 |
| Quercetin | EGF (1nql) | −11.5 |
| Stigmasterol | ANXA1 (1mcx) | −11.0 |
| Stigmasterol | IL6 (4cni) | −10.0 |
| Stigmasterol | EGFR (5ug9) | −9.3 |
| Quercetin | EGF (1nql) | −9.0 |
| Kaempferol | IL6 (4cni) | −8.8 |
| Kaempferol | TP53 (3d06) | −8.7 |
| Kaempferol | EGF (1nql) | −8.5 |
| Stigmasterol | TP53 (3d06) | −8.3 |
| Stigmasterol | MAPK1 (2waj) | −7.5 |
| Kaempferol | ANXA1 (1mcx) | −7.2 |
| Quercetin | TP53 (3d06) | −6.9 |
| Quercetin | ANXA1 (1mcx) | −5.7 |
| Kaempferol | MAPK1 (2waj) | −5.0 |
| Quercetin | IL6 (4cni) | −3.8 |
| Quercetin | MAPK1 (2waj) | −2.8 |
Figure 7Schematic diagram of the molecular docking model. (a) Schematic diagram of docking between EGF and quercetin. (b) Schematic diagram of docking between EGF and stigmasterol. (c) Schematic diagram of docking between EGFR and kaempferol.
Figure 8Diagram of signaling pathways associated with infertility.